Y BioLogics and AB Chem Bio Announce Business Alliance for ADC Anticancer Drug Development
Y BioLogics and AB Chem Bio Sign Business Alliance Agreement for ADC Anticancer Drug Development A Step Forward in Advancing Anticancer Technology In a significant move towards advancing antibody-drug conjugate (ADC) anticancer drug development, Y BioLogics, an antibody drug development platform company, has entered into a business alliance agreement with AB Chem Bio, a bio-enterprise […]
Samjin Pharmaceutical and Epibiotech Partner for Joint Research on Antibody and Gene Therapy Technologies
Samjin Pharmaceutical Signs MOU with Epibiotech for Antibody and Gene Therapy Development In an exciting collaboration, Samjin Pharmaceutical, led by CEO Choi Yong-joo, has announced a strategic partnership with Epibiotech, a renowned research and development company specializing in cutting-edge hair loss treatments. This partnership aims to advance the development of antibody-drug conjugates (ADC) and gene […]
Celltrion Group Completes Merger with Celltrion Healthcare, Pursues Merger with Celltrion Pharmaceuticals
Celltrion Completes Merger, Pursues Further Expansion Celltrion Group Makes Major Leap in Global Pharma Industry Seoul, September 17th – Celltrion Group, a leading biotechnology company, has finalized its merger with Celltrion Healthcare and announced plans to pursue a merger with Celltrion Pharmaceuticals in the near future. This strategic move positions Celltrion as a global powerhouse […]
Ministry of Food and Drug Safety Releases Clinical Pharmacology Consideration Guidelines for Antibody-Drug Combinations
Ministry of Food and Drug Safety Releases Guidelines for Antibody-Drug Combinations In a move to support the development of Antibody-Drug Combinations (ADCs) and expand treatment options for patients, the Ministry of Food and Drug Safety, led by Minister Oh Yoo-gyeong, has published the ‘Clinical Pharmacology Consideration Guidelines for Antibody-Drug Combinations’. ADCs are targeted anticancer drugs […]
SK Holdings Selects Brain Asset Management as Preferred Bidder for SK Pharmteco Pre-IPO Investment
SK Holdings Selects Brain Asset Management as Preferred Bidder for SK Pharmteco’s Pre-IPO Equity Investment On the 18th, SK holdings announced that it has chosen Brain Asset Management as the preferred bidder for the pre-IPO (pre-IPO equity investment) of SK Pharmteco, a contract development and manufacturing subsidiary (CDMO) specializing in pharmaceutical raw materials. The investment […]
Surviving Amidst Challenges: Canaph Therapeutics and the TMEkine Platform
**Steintech Bio Season Ⅱ: Bioventures Face Challenges Amidst Rising IPO Threshold** Investment in domestic bioventures has been declining rapidly since last year, leading to a rise in the threshold for initial public offerings (IPOs). As a result, many biotech companies are struggling with their business operations and focusing on survival rather than growth. Against this […]
Lotte Biologics Signs Joint Shipment Research and Development Agreement with Carnaphtherapeutics to Build ADC Technology Platform
Lotte Biologics Collaborates with Carnaphtherapeutics to Develop Antibody Drug Technology Platform In an effort to strengthen its capabilities in the field of antibody-drug conjugates (ADC), Lotte Biologics, led by CEO Lee Won-jik, has entered into a joint research and development agreement with domestic bio-enterprise Carnaphtherapeutics, headed by CEO Lee Byeong-cheol. The collaboration aims to build […]
[2023바이오USA/영상] “The status of K-Bio has changed”… Targeting global markets such as Prestige Biopharma and Lotte Bilogics
-Samsung Biologics, cut the ‘5th factory’ by 5 months ‘actively responding to demand’ – Prestige Biopharma · Prestige Bilogics, executive meetings with ‘Big Pharma’ -Lotte Bilogics, targeting foreign markets, ‘ensuring competitiveness’ [앵커] At this Bio USA 2023, discussions on the commercialization of CDMO and ADC double antibodies were prominent. In particular, there was great interest […]
Orum Therapeutic unveils clinical design of HER2 target ‘GSPT1 degrader’ at ASCO
Orum Therapeutics (CEO Lee Seung-joo) presented HER2-targeted GSPT1 (G1 to S phase transition) for patients with advanced solid tumors expressing HER2 at the American Society of Clinical Oncology (ASCO) held in Chicago, USA from 2nd (local time) to 5th. We will disclose the design of a phase 1 clinical trial of protein 1) decomposer ‘ORM-5029 […]
[허가/임상] Phase 3 approval of Elaire, the first ADC treatment for ovarian cancer
Last week (May 22-26), a total of 23 items received item approval from the Ministry of Food and Drug Safety. There were 13 prescription drugs and 10 over the counter drugs. Approved items are approved for various indications, including type 2 diabetes, major depressive disorder, Parkinson’s syndrome, hyperlipidemia, macular degeneration, and retinopathy. The antidepressant ‘Nupram […]
